Kuros completes enrolment in phase IIb trial of bone regeneration product
This article was originally published in Clinica
Executive Summary
Kuros Biosurgery (Zurich, Switzerland) has enrolled the final patient in a phase IIb trial of its lead bone regeneration product, KUR-111, in tibial plateau fractures. The product is a mouldable putty that is applied directly to the fracture site. The 183-patient trial will evaluate whether the material can provide physical support and promote bone healing via the release of parathyroid hormone as successfully as autografting, the current standard of care. The primary endpoint is the rate of radiological fracture healing 16 weeks after surgery. The trial will also assess the safety of KUR-111, with results expected in early 2010.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.